secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harpoon Therapeutics, Inc. (—)
CIK:        0001708493
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0001193125-23-080536
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 5.03, 2.02, 2.03, 3.02, 3.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harpoon raises $25M via preferred equity, posts Q4 2022 net loss of $18.4M
--------------------------------------------------------------------------

- Closed $25M private placement of 8% Series A redeemable preferred stock and warrants ($0.9789 strike, 8-yr).
- Q4 2022 net loss $18.4M; full year 2022 net loss $67.7M (vs $116.7M prior year).
- Q4 revenue $4.1M; full year revenue $31.9M (vs $23.7M prior year).
- Cash, equivalents and marketable securities $53.1M at Dec 31, 2022; cash runway into H2 2024.
- HPN217 (BCMA) Phase 1 dose exploration to complete H1 2023; data presentation expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708493/000119312523080536/0001193125-23-080536-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708493/000119312523080536/d422544d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-080536

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer